Inozyme Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INZ701 / Inozyme Pharma
NCT06046820: The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Active, not recruiting
3
27
Europe, Canada, US, RoW
INZ-701, (rhENPP1-Fc)., Control Arm (Conventional Therapy)
Inozyme Pharma
Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
01/26
02/26
NCT06462547: ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Recruiting
2
200
Europe, US
INZ-701, rhENPP1-Fc
Inozyme Pharma
Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets Type 2
11/30
12/30
NCT06739980: The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency

Withdrawn
2
40
NA
INZ-701, (rhENPP1-Fc).
Inozyme Pharma
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy 1
03/27
03/28
2020-004000-33: A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of INZ-701 in Adults with ABCC6 Deficiency causing Pseudoxanthoma elasticum (PXE)

Not yet recruiting
1/2
9
Europe
INZ-701, INZ-701, Lyophilisate for solution for injection
Inozyme Pharma, Inc., Inozyme Pharma, Inc.
Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE), ABCC6 Deficiency causing a condition called Pseudoxanthoma elasticum, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT04686175: Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Completed
1/2
9
Europe, Canada, US
INZ-701, rhENPP1-Fc
Inozyme Pharma
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
10/24
12/24
NCT05030831 / 2020-004000-33: Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Completed
1/2
10
Europe, US
INZ-701, rhENPP1-Fc
Inozyme Pharma, IQVIA Biotech
ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum, Generalized Arterial Calcification of Infancy
07/24
07/24
NCT06283589: The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

Completed
1
11
US
INZ-701, (rhENPP1-Fc).
Inozyme Pharma
Calciphylaxis
07/24
12/24
ENERGY, NCT05734196: The Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

Recruiting
1
16
Europe, US
INZ-701, (rhENPP1-Fc).
Inozyme Pharma
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
03/26
04/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INZ701 / Inozyme Pharma
NCT06046820: The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Active, not recruiting
3
27
Europe, Canada, US, RoW
INZ-701, (rhENPP1-Fc)., Control Arm (Conventional Therapy)
Inozyme Pharma
Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
01/26
02/26
NCT06462547: ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

Recruiting
2
200
Europe, US
INZ-701, rhENPP1-Fc
Inozyme Pharma
Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets Type 2
11/30
12/30
NCT06739980: The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency

Withdrawn
2
40
NA
INZ-701, (rhENPP1-Fc).
Inozyme Pharma
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy 1
03/27
03/28
2020-004000-33: A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of INZ-701 in Adults with ABCC6 Deficiency causing Pseudoxanthoma elasticum (PXE)

Not yet recruiting
1/2
9
Europe
INZ-701, INZ-701, Lyophilisate for solution for injection
Inozyme Pharma, Inc., Inozyme Pharma, Inc.
Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE), ABCC6 Deficiency causing a condition called Pseudoxanthoma elasticum, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT04686175: Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Completed
1/2
9
Europe, Canada, US
INZ-701, rhENPP1-Fc
Inozyme Pharma
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
10/24
12/24
NCT05030831 / 2020-004000-33: Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Completed
1/2
10
Europe, US
INZ-701, rhENPP1-Fc
Inozyme Pharma, IQVIA Biotech
ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum, Generalized Arterial Calcification of Infancy
07/24
07/24
NCT06283589: The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

Completed
1
11
US
INZ-701, (rhENPP1-Fc).
Inozyme Pharma
Calciphylaxis
07/24
12/24
ENERGY, NCT05734196: The Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

Recruiting
1
16
Europe, US
INZ-701, (rhENPP1-Fc).
Inozyme Pharma
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
03/26
04/26

Download Options